Avery Therapeutics Selected for Bioscience Entrepreneurship Program














Avery Therapeutics is one of six Arizona startup firms selected by the Flinn Foundation to participate in its 2018 Bioscience Entrepreneurship Program. Each firm receives $30,000 in funding support and program services administered through a nonprofit partner.

Avery, the only Tucson-based startup selected, has its roots in a University of Arizona Sarver Heart Center lab. Steve Goldman, MD, professor of medicine and research scientist, collaborated with Jordan Lancaster, PhD, an assistant research scientist at Sarver Heart Center who obtained his doctoral degree from the UA College of Medicine - Tucson Department of Physiology. They co-founded Avery.

Dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, Avery’s lead product, MyCardia, is a tissue-engineered heart graft developed to treat heart failure. It is in the pre-clinical development phase. MyCardia is positioned to be the world’s first off-the-shelf product for treating heart failure, said Dr. Goldman, Avery’s chief medical officer. Jen Watson Koevary, PhD, Avery’s chief operating officer, earned her doctorate from the UA department of biomedical engineering.

Read more about Avery Therapeutics at Tech Launch Arizona.